 Connection
Lee Newman to Berylliosis
This is a "connection" page, showing publications Lee Newman has written about Berylliosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.426 |
|
|
|
-
Smith DE, Golden AP, Stange AW, Barker E, Mroz M, Barón AE, Ghosh D, Maier L, Cragle D, Newman LS. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT). Am J Ind Med. 2018 07; 61(7):592-604.
Score: 0.480
-
Tooker BC, Ozawa K, Newman LS. CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge. J Immunotoxicol. 2016 05; 13(3):417-27.
Score: 0.410
-
Tooker BC, Brindley SM, Chiarappa-Zucca ML, Turteltaub KW, Newman LS. Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway. J Immunotoxicol. 2015 Apr-Jun; 12(2):181-7.
Score: 0.369
-
Tooker BC, Bowler RP, Orcutt JM, Maier LA, Christensen HM, Newman LS. SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease. Occup Environ Med. 2011 Oct; 68(10):759-64.
Score: 0.292
-
Mroz MM, Maier LA, Strand M, Silviera L, Newman LS. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. Am J Ind Med. 2009 Oct; 52(10):762-73.
Score: 0.266
-
Sawyer RT, Fontenot AP, Barnes TA, Parsons CE, Tooker BC, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Hagman J, Newman LS. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol. 2007 Feb; 36(2):191-200.
Score: 0.216
-
Sawyer RT, Abraham JL, Daniloff E, Newman LS. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J Occup Environ Med. 2005 Dec; 47(12):1218-26.
Score: 0.204
-
Newman LS, Maier LA, Martyny JW, Mroz MM, VanDyke M, Sackett HM. Beryllium workers' health risks. J Occup Environ Hyg. 2005 Jun; 2(6):D48-50.
Score: 0.197
-
Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2005 Jan 01; 171(1):54-60.
Score: 0.188
-
Sackett HM, Maier LA, Silveira LJ, Mroz MM, Ogden LG, Murphy JR, Newman LS. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J Occup Environ Med. 2004 Sep; 46(9):953-61.
Score: 0.187
-
Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, Silveira L, Newman LS. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol. 2004 Oct; 31(4):470-7.
Score: 0.186
-
Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Newman LS. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004 Jul; 31(1):122-30.
Score: 0.181
-
Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet. 2004 Feb 07; 363(9407):415-6.
Score: 0.180
-
Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, Newman LS. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003 Dec 15; 171(12):6910-8.
Score: 0.178
-
Maier LA, Kittle LA, Mroz MM, Newman LS. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med. 2003 Jun; 43(6):592-601.
Score: 0.172
-
Kittle LA, Sawyer RT, Fadok VA, Maier LA, Newman LS. Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc Diffuse Lung Dis. 2002 Jun; 19(2):101-13.
Score: 0.160
-
Maier L, Martyny J, Mroz M, McGrath D, Lympany P, duBois R, Zhang L, Murphy J, Newman LS. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. Chest. 2002 Mar; 121(3 Suppl):81S.
Score: 0.157
-
Sawyer RT, Maier LA, Kittle LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol. 2002 Feb; 2(2-3):249-61.
Score: 0.157
-
Harris J, Bartelson BB, Barker E, Balkissoon R, Kreiss K, Newman LS. Serum neopterin in chronic beryllium disease. Am J Ind Med. 1997 Jul; 32(1):21-6.
Score: 0.114
-
Daniloff EM, Lynch DA, Bartelson BB, Newell JD, Bernstein SM, Newman LS. Observer variation and relationship of computed tomography to severity of beryllium disease. Am J Respir Crit Care Med. 1997 Jun; 155(6):2047-56.
Score: 0.113
-
Newman LS. Immunology, genetics, and epidemiology of beryllium disease. Chest. 1996 Mar; 109(3 Suppl):40S-43S.
Score: 0.104
-
Inoue Y, Cornebise M, Daniloff E, Lloyd J, Tinkle S, King TE, Newman LS. Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. Chest. 1996 Mar; 109(3 Suppl):43S-44S.
Score: 0.104
-
Newman LS. Beryllium disease and sarcoidosis: clinical and laboratory links. Sarcoidosis. 1995 Mar; 12(1):7-19.
Score: 0.097
-
Maier LA, Barkes BQ, Mroz M, Rossman MD, Barnard J, Gillespie M, Martin A, Mack DG, Silveira L, Sawyer RT, Newman LS, Fontenot AP. Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. Respir Med. 2012 Dec; 106(12):1810-3.
Score: 0.082
-
Martin AK, Mack DG, Falta MT, Mroz MM, Newman LS, Maier LA, Fontenot AP. Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. J Allergy Clin Immunol. 2011 Nov; 128(5):1100-6.e1-5.
Score: 0.076
-
Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL, Tankersley WG, Wells SM, Newman LS, Maier LA. Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occup Environ Med. 2011 Nov; 68(11):842-8.
Score: 0.074
-
Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, Sato H, Newman LS, Maier LA. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med. 2011 Jun 15; 183(12):1680-8.
Score: 0.074
-
Dobis DR, Sawyer RT, Gillespie MM, Huang J, Newman LS, Maier LA, Day BJ. Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med. 2008 May 01; 177(9):1002-11.
Score: 0.059
-
Jonth AC, Silveira L, Fingerlin TE, Sato H, Luby JC, Welsh KI, Rose CS, Newman LS, du Bois RM, Maier LA. TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol. 2007 Sep 15; 179(6):4255-62.
Score: 0.058
-
Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LA, Newman LS, Kotzin BL. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest. 2005 Oct; 115(10):2886-93.
Score: 0.050
-
Fontenot AP, Gharavi L, Bennett SR, Canavera SJ, Newman LS, Kotzin BL. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J Clin Invest. 2003 Sep; 112(5):776-84.
Score: 0.044
-
Frome EL, Newman LS, Cragle DL, Colyer SP, Wambach PF. Identification of an abnormal beryllium lymphocyte proliferation test. Toxicology. 2003 Feb 01; 183(1-3):39-56.
Score: 0.042
-
Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest. 2002 Nov; 110(10):1473-82.
Score: 0.041
-
Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol. 2001 Jul; 100(1):4-14.
Score: 0.038
-
Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci U S A. 2000 Nov 07; 97(23):12717-22.
Score: 0.036
-
Kreiss K, Miller F, Newman LS, Ojo-Amaize EA, Rossman MD, Saltini C. Chronic beryllium disease--from the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol. 1994 May; 71(2):123-9.
Score: 0.023
-
Dobis DR, Sawyer RT, Gillespie MM, Newman LS, Maier LA, Day BJ. Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production. Am J Respir Cell Mol Biol. 2010 Oct; 43(4):458-64.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|